We scan new podcasts and send you the top 5 insights daily.
Unlike targets like FR-alpha and HER2 that require high expression thresholds to yield significant clinical responses, B7-H4 exhibits expression rates between 80% and 90% across ovarian and endometrial cancers. This pervasive prevalence may allow broader patient eligibility without requiring restrictive biomarker cutoffs.
The introduction of ADCs into frontline ovarian cancer treatment creates a new challenge: conflicting biomarkers. A patient's tumor might be positive for both HER2 (an ADC target) and a BRCA mutation (a PARP inhibitor target), forcing clinicians to choose between two effective targeted therapies without clear guidance.
Clinicians should view HRD scores as a spectrum rather than a simple positive/negative result. For a patient with a score near the arbitrary cutoff and an excellent clinical response to platinum, oncologists may advocate for insurance coverage of PARP inhibitors.
NCCN guidelines for folate receptor alpha and HER2 in ovarian cancer allow treatment at lower expression levels than initial trials. This is driven not only by data showing activity in these groups but also by the fact that the original smaller biotech developers had limited resources for expansive trials beyond the highest-expressing cohorts, a commercial factor influencing current clinical guidance.
Unlike in breast cancer, where HER2 IHC 2+ requires FISH confirmation, in gynecologic cancers an IHC 2+ result is often considered directly actionable for prescribing HER2-targeted ADCs like T-DXD. This reflects a different, less stringent clinical standard for biomarker-guided therapy in this setting.
Unlike early ADCs requiring high biomarker expression (e.g., mirvetuximab), next-generation agents show efficacy even in low-expressing tumors. This allows for broader, "all-comer" clinical trial inclusion criteria instead of biomarker-gated entry, potentially expanding patient access to these novel therapies.
While PARP inhibitors show some effect in all patients, clinical data revealed a significant survival advantage only in the HRD-positive subgroup. This has led to an FDA restriction, making biomarker testing a prerequisite for this class of drugs.
The future of GYN oncology immunotherapy is diverging. For responsive cancers like endometrial, the focus is on refining biomarkers and overcoming resistance. For historically resistant cancers like ovarian, the strategy shifts to using combinatorial approaches (e.g., CAR-NKs, vaccines) to fundamentally alter the tumor microenvironment itself, making it more receptive to an immune response.
Dr. Alvarez-Secord explains that unlike FR-alpha or HER2 ADCs that target growth signals, B7-H4 is embedded in immune regulation. Administering a B7-H4 ADC relieves microenvironment immunosuppression while tumor cell kill releases neoantigens, creating synergy when paired with checkpoint inhibitors like dostarlimab.
The glucocorticoid receptor antagonist relacorilant does not require biomarker testing for patient selection. Its target is ubiquitously expressed in over 95% of ovarian cancer tissues, making it a broadly applicable therapy without the need for additional screening.
Next-generation topoisomerase I payload ADCs are showing up to 50% response rates in platinum-resistant ovarian cancer without requiring high biomarker expression. Unlike mirvetuximab or trastuzumab deruxtecan, these emerging agents could broaden clinical accessibility to broader patient populations without upfront IHC biomarker stratification.